AstraZeneca: Tagrisso big in Japan

(CercleFinance.com) - AstraZeneca announces that its Tagrisso (osimertinib) has been approved in Japan when combined with pemetrexed and platinum-based chemotherapy as first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations.


This approval is based on the results of a phase III trial showing that this protocol reduced the risk of disease progression or death by 38% compared with Tagrisso alone.

Median progression-free survival was 25.5 months for the combination, compared with 16.7 months for Tagrisso alone. The overall survival results are promising but still immature.

Lung cancer is the leading cause of cancer death in Japan, with around 135,000 new cases of NSCLC each year, 36% of which have EGFR mutations.


Copyright (c) 2024 CercleFinance.com. All rights reserved.